Gujarat Themis Biosyn Limited (GTBL) has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Rajneesh Anand as Non-Executive Non-Independent Director, while continuing to demonstrate strong financial performance in its recent quarterly results.

Postal Ballot for Director Appointment

GTBL has issued a postal ballot notice to shareholders for the appointment of Mr. Rajneesh Anand as Non-Executive Non-Independent Director. The key details of the postal ballot are:

The company has engaged Central Depository Services (India) Limited (CDSL) to provide remote e-voting facility for the postal ballot process.

Director Profile and Remuneration

Mr. Rajneesh Anand brings extensive experience to the board:

• Mechanical Engineering graduate from M.S. University, Baroda
• Postgraduate in Management from Jamnalal Bajaj Institute, Mumbai
• Associated with Themis Group since 1977 (over four decades)
• Currently serves as Director of Themis Medicare Limited
• Holds 1,69,770 shares in the company

The proposed remuneration of ₹10.00 lakhs per month will be paid as professional fees under Section 197(4) of the Companies Act, 2013, for strategic advisory and supervisory services.

Financial Performance Highlights

The company's Q2 financial results demonstrate robust growth across key metrics:

GTBL's performance shows strong improvement in both revenue growth and profitability margins.

Operational Expansion

GTBL has successfully completed a major expansion of its manufacturing capabilities:

This expansion significantly strengthens GTBL's fermentation capabilities and positions the company to meet growing demand for pharmaceutical ingredients.

Strategic Outlook

With the proposed appointment of an experienced industry veteran and the successful expansion of manufacturing capacity, Gujarat Themis Biosyn appears well-positioned for continued growth in the bulk drugs manufacturing sector. The company's focus on enhancing production capabilities and strengthening board expertise aligns with its strategic objectives in the pharmaceutical industry.

Gujarat Themis Biosyn Limited (GTBL) has marked a significant milestone in its growth trajectory with the commencement of commercial production at its expanded Fermentation Block in Vapi, Gujarat. The company officially began production of Rifamycin-S and Rifamycin-O on October 18, 2025, signaling a substantial boost to its manufacturing capabilities.

Capacity Expansion Details

The expansion project has more than doubled GTBL's fermentation capacity, as detailed in the following table:

This significant increase in capacity positions GTBL to capitalize on growth opportunities within the fermentation segment, particularly in the production of multiple fermentation products.

Strategic Implications

The expansion of the Fermentation Block at Vapi carries several strategic implications for GTBL:

1. Enhanced Production Capabilities: The more than doubled capacity allows GTBL to significantly increase its output of fermentation products.
2. Product Diversification: The expanded facilities enable the company to produce a wider range of fermentation products, potentially opening new market opportunities.
3. Market Position: With increased capacity, GTBL is better positioned to meet growing market demand and potentially increase its market share in the fermentation segment.
4. Operational Efficiency: The new facilities may lead to improved operational efficiencies and economies of scale.

Company's Statement

In its official communication to the stock exchanges, GTBL stated, "With this capacity expansion, the Company is in a strong position to capitalise on the significant growth opportunities in the fermentation segment."

The commencement of commercial production at the expanded facility marks a pivotal moment for Gujarat Themis Biosyn Limited. As the company leverages its enhanced manufacturing capabilities, stakeholders will be keenly watching how this translates into business growth and market performance in the coming quarters.